Greenleaf Peter 4

What Happened

• Peter Greenleaf, a Director of Pelthos Therapeutics, sold a total of 797 shares on 2026-04-02 in two open-market transactions. The filing reports 420 shares at a weighted-average price of $20.52 (reported proceeds ≈ $8.6K) and 377 shares at $21.36 (reported proceeds ≈ $8.1K), for roughly $16.7K in total proceeds. This was a sale (S), not a purchase.

Key Details

• Transaction dates: 2026-04-02; Form 4 filed 2026-04-06 (timely).
• Reported prices/ranges: 420 shares reported at WA $20.52 (executed across $20.30–$20.78 per footnote); 377 shares reported at WA $21.36 (executed across $21.31–$22.03 per footnote).
• Reason given: Sold pursuant to a Rule 10b5-1 plan adopted 12/16/2025 to satisfy estimated tax obligations from the vesting of restricted stock units (footnote).
• Shares owned after transaction: Not specified in the details you provided—see the full Form 4 (Accession 0001919246-26-000052) for total holdings.
• Additional disclosure: The filer offers to provide, on request, full trade-by-trade counts and prices underlying the weighted averages.

Context

• This sale was executed under a pre-established 10b5-1 plan for tax withholding related to RSU vesting, which is a common, planned reason for insider sales and does not necessarily indicate the director's view on the stock. Purchases generally carry more weight as signals than routine tax-related sales. For the complete Form 4 and exact post-transaction holdings, refer to the SEC filing (Accession 0001919246-26-000052).